AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12616127 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO) 300 IU/kg body weight plus 100 mg iron intravenously
Number of subjects: 63
Study 12616127 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication and iron
Number of subjects: 63
Study 12616127 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 63
Study 10688215 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium and sodium diatrizoate (Gastrografin) (n = 48)
Number of subjects: 98
Study 10688215 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contrast) (n = 50)
Number of subjects: 98
Study 9499605 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% zinc sulphate
Number of subjects: 63
Study 9499605 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% sodium chloride
Number of subjects: 63
Study 9499605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent antimony compound (sodium stibogluconate)
Number of subjects: 63
Study 9499605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 63
Study 8372752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 0
Study 8372752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3793333 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg)
Number of subjects: 12
Study 3793333 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem (60 mg)
Number of subjects: 12
Study 3793333 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (80 mg)
Number of subjects: 12
Study 3793333 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29220542 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg BID
Number of subjects: 250
Study 29220542 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg QW
Number of subjects: 250
Study 29220542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 28408729 — intervention group
Group type: EXPERIMENTAL
Intervention: Menatetrenone and risedronate plus calcium supplementation
Number of subjects: 0
Study 28408729 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24461794 — intervention group
Group type: EXPERIMENTAL
Intervention: Skimmed milk
Number of subjects: 193
Study 24461794 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 193
Study 24461794 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 193
Study 24461794 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 193
Study 24461794 — intervention group
Group type: COMPARATOR
Intervention: Pre-test control group
Number of subjects: 193
Study 22446676 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and verbal feedback (Intervention Group, IG)
Number of subjects: 19
Study 22446676 — intervention group
Group type: COMPARATOR
Intervention: No feedback (Control Group, CG)
Number of subjects: 19
Study 20959578 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d)
Number of subjects: 16608
Study 20959578 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 16608
Study 20959578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study 18063394 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with TnI elevation (20 patients, 47%)
Number of subjects: 43
Study 18063394 — intervention group
Group type: COMPARATOR
Intervention: Patients without TnI elevation (23 patients, 53%)
Number of subjects: 43
Study 18063394 — intervention group
Group type: EXPERIMENTAL
Intervention: TnI elevation as an independent predictor
Number of subjects: 43
Study 15910557 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (RSV)
Number of subjects: 263
Study 15910557 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (ATV)
Number of subjects: 263
Study 15910557 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 263
Study 12579625 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Urogenital Distress Inventory (UDI)
Number of subjects: 2238
Study 12579625 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Incontinence Impact Questionnaire (IIQ)
Number of subjects: 2238
Study 12579625 — intervention group
Group type: EXPERIMENTAL
Intervention: Criterion and construct validity tests of UDI and IIQ subscales
Number of subjects: 2238
Study 10473054 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (1 microg/kg/h in saline) infusion
Number of subjects: 8
Study 10473054 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 8697744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral presentation of letter pairs (verbal matching task)
Number of subjects: 27
Study 8697744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral presentation of dot pattern pairs (nonverbal matching task)
Number of subjects: 27
Study 8697744 — intervention group
Group type: COMPARATOR
Intervention: Unilateral presentation of letter pairs (verbal matching task)
Number of subjects: 27
Study 8697744 — intervention group
Group type: COMPARATOR
Intervention: Unilateral presentation of dot pattern pairs (nonverbal matching task)
Number of subjects: 27
Study 1753737 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (40 minutes including warm-up and cool-down)
Number of subjects: 85
Study 1753737 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic relaxation (30 minutes listening to instructions)
Number of subjects: 85
Study 1753737 — intervention group
Group type: COMPARATOR
Intervention: Control group (excused after anxiety induction)
Number of subjects: 85
Study 6138053 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 0
Study 6138053 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 30 mg
Number of subjects: 0
Study 6138053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30917691 — intervention group
Group type: EXPERIMENTAL
Intervention: OneTouch Reveal® diabetes app with telemedical features
Number of subjects: 5
Study 29741923 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP treatment (n = 27)
Number of subjects: 50
Study 29741923 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n = 23)
Number of subjects: 50
Study 29231359 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint pressure therapy applied at uterine orifice dilation of 2 to 3 cm, 5 to 6 cm, 7 to 8 cm, and 9 to 10 cm.
Number of subjects: 120
Study 29231359 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint pressure therapy (observation group)
Number of subjects: 120
Study 29231359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupoint pressure therapy)
Number of subjects: 120
Study 24597699 — intervention group
Group type: EXPERIMENTAL
Intervention: Locked Volar Plate (VP)
Number of subjects: 72
Study 24597699 — intervention group
Group type: COMPARATOR
Intervention: External Fixator (EF)
Number of subjects: 72
Study 21947244 — intervention group
Group type: COMPARATOR
Intervention: Coiling without DCI
Number of subjects: 2143
Study 21947244 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 2143
Study 21947244 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling with DCI
Number of subjects: 2143
Study 21947244 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping without DCI
Number of subjects: 2143
Study 21947244 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping with DCI
Number of subjects: 2143
Study 21947244 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipping and DCI
Number of subjects: 2143
Study 21947244 — intervention group
Group type: EXPERIMENTAL
Intervention: Coiling and DCI (for patients treated within 4 days)
Number of subjects: 2143
Study 19908346 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomy plus splenectomy
Number of subjects: 466
Study 17262713 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar gel
Number of subjects: 10
Study 17262713 — intervention group
Group type: COMPARATOR
Intervention: Iso-osmolar gel
Number of subjects: 10
Study 15274066 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon-alpha (9 MU daily) - Arm A
Number of subjects: 103
Study 15274066 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon-alpha (9 MU daily) plus oral 13-cis retinoic acid (1 mg/kg) - Arm B
Number of subjects: 103
Study 12471281 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal packing with an airway (n=20)
Number of subjects: 40
Study 12471281 — intervention group
Group type: COMPARATOR
Intervention: Nasal packing without an airway (n=20)
Number of subjects: 40
Study 10234421 — intervention group
Group type: EXPERIMENTAL
Intervention: Public performance condition
Number of subjects: 0
Study 10234421 — intervention group
Group type: COMPARATOR
Intervention: Private performance condition
Number of subjects: 0
Study 10234421 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic pressure responses
Number of subjects: 0
Study 7708179 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 7708179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2667865 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (sCT) 100 U injected subcutaneously every second day
Number of subjects: 36
Study 2667865 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 36
Study 145230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbitone i.v.
Number of subjects: 135
Study 145230 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol i.v.
Number of subjects: 135
Study 145230 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 135
Study 145230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbitone
Number of subjects: 135
Study 145230 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 135
Study 145230 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbitone or Droperidol
Number of subjects: 135
Study 30765033 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 150
Study 30765033 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 150
Study 28069970 — intervention group
Group type: EXPERIMENTAL
Intervention: Welding employment (≥1 year)
Number of subjects: 53454
Study 28069970 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundry work employment (≥1 year)
Number of subjects: 53454
Study 28069970 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint employment in welding and foundry work (≥1 year)
Number of subjects: 53454
Study 28069970 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing years of employment in welding
Number of subjects: 53454
Study 28069970 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing years of employment in foundry work
Number of subjects: 53454
Study 25799356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) system at 30 L/minute
Number of subjects: 30
Study 25799356 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow (NHF) system at 50 L/minute
Number of subjects: 30
Study 25799356 — intervention group
Group type: COMPARATOR
Intervention: Oxygen at 5 L/minute through a nasal cannula (NC5 group)
Number of subjects: 30
Study 24195548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg) plus abacavir-lamivudine once daily (DTG-ABC-3TC group)
Number of subjects: 833
Study 24195548 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with efavirenz-tenofovir disoproxil fumarate-emtricitabine once daily (EFV-TDF-FTC group)
Number of subjects: 833
Study 24195548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus abacavir-lamivudine
Number of subjects: 833
Study 24195548 — intervention group
Group type: COMPARATOR
Intervention: efavirenz-tenofovir disoproxil fumarate-emtricitabine
Number of subjects: 833
Study 21165629 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Diet (HC; 60% carbohydrate, 20% fat, 20% protein)
Number of subjects: 18
Study 21165629 — intervention group
Group type: COMPARATOR
Intervention: High-Fat Diet (HF; 50% fat, 30% carbohydrate, 20% protein)
Number of subjects: 18
Study 21165629 — intervention group
Group type: COMPARATOR
Intervention: High-Carbohydrate Diet (HC) vs High-Fat Diet (HF)
Number of subjects: 18
Study 19682096 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment under a comprehensive dental programme
Number of subjects: 139
Study 17655888 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried-bonito broth
Number of subjects: 48
Study 17655888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15656462 — intervention group
Group type: EXPERIMENTAL
Intervention: OpSite Post‐Op
Number of subjects: 300
Study 15656462 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm with pad
Number of subjects: 300
Study 15656462 — intervention group
Group type: COMPARATOR
Intervention: Primapore
Number of subjects: 300
Study 12384264 — intervention group
Group type: EXPERIMENTAL
Intervention: Enbucrilate tissue adhesive
Number of subjects: 62
Study 12384264 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular polyglycolic acid sutures
Number of subjects: 62
Study 9869105 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Epirubicin (EPI) 120 mg/m2 plus Cisplatin (CP) 60 mg/m2
Number of subjects: 228
Study 9869105 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (VNR) 25 mg/m2 plus Cisplatin (CP) 60 mg/m2
Number of subjects: 228
Study 7657856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1600 mg per day)
Number of subjects: 14
Study 7657856 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (80 mg per day)
Number of subjects: 14
Study 7657856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2621066 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Thomas' hospital solution (potassium concentration 20 mmol/l) - group A
Number of subjects: 163
Study 2621066 — intervention group
Group type: COMPARATOR
Intervention: Ringer's injection (potassium concentration 4 mmol/l) - group B
Number of subjects: 163
Study 4834097 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction dose of methohexitone 1.0 mg/kg
Number of subjects: 26
Study 4834097 — intervention group
Group type: COMPARATOR
Intervention: Induction dose of methohexitone 1.4 mg/kg
Number of subjects: 26
Study 31548678 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 31548678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28667230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination povidone iodine and sodium fluoride dental varnish
Number of subjects: 284
Study 28667230 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride dental varnish
Number of subjects: 284
Study 25692251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic pressure regulation (ITPR, -12 cm H2O vacuum)
Number of subjects: 7
Study 25692251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic pressure regulation (ITPR)
Number of subjects: 7
Study 25692251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (device but no vacuum)
Number of subjects: 7
Study 24330505 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate Schools intervention group
Number of subjects: 0
Study 24330505 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21762878 — intervention group
Group type: EXPERIMENTAL
Intervention: high-frequency (10 Hz) rTMS directed at the SFG
Number of subjects: 15
Study 21762878 — intervention group
Group type: EXPERIMENTAL
Intervention: low-frequency (1 Hz) rTMS directed at the SFG
Number of subjects: 15
Study 21762878 — intervention group
Group type: COMPARATOR
Intervention: low-frequency (1 Hz) rTMS directed at the motor cortex
Number of subjects: 15
Study 19154844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna bathing program (3 times a week for 4 weeks at 60±1 degrees C, 15-20 minutes per session)
Number of subjects: 9
Study 19154844 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna bathing program
Number of subjects: 9
Study 19154844 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual activities and medications)
Number of subjects: 9
Study 15650512 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 168
Study 10078849 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise/energy balance (EI=EE=15.1+/‐0.6 MJ)
Number of subjects: 8
Study 10078849 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise/negative energy balance (EI=11.8+/‐0.8 MJ, EE=15.1+/‐0.8 MJ)
Number of subjects: 8
Study 10078849 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise/positive energy balance (EI=18.6+/‐0.7 MJ, EE=15.1+/‐0.6 MJ)
Number of subjects: 8
Study 10078849 — intervention group
Group type: COMPARATOR
Intervention: no exercise/energy balance (EI=EE=11.8+/‐0.8 MJ)
Number of subjects: 8
Study 7594512 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose TNFR:Fc (10 mg/m2 i.v.)
Number of subjects: 18
Study 7594512 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose TNFR:Fc (60 mg/m2 i.v.)
Number of subjects: 18
Study 7594512 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR:Fc (both doses)
Number of subjects: 18
Study 7594512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2299797 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term hemodialysis (HD) patients
Number of subjects: 0
Study 2299797 — intervention group
Group type: EXPERIMENTAL
Intervention: First dialysis session in uremic (UR) patients
Number of subjects: 0
Study 2299797 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dialysis session
Number of subjects: 0
Study 2299797 — intervention group
Group type: COMPARATOR
Intervention: Dialysis membrane (CUP or PAN-AN 69)
Number of subjects: 0
Study 2299797 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term HD patients
Number of subjects: 0
Study 7033351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (500 mg tablets, two tablets after meals and at bedtime)
Number of subjects: 216
Study 7033351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tablets after meals and at bedtime)
Number of subjects: 216
Study 7033351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 216
Study 7033351 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests
Number of subjects: 216
Study 28803925 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish screening protocol (2-year interval, PSA cut-off 3.0 ng/ml)
Number of subjects: 31967
Study 28803925 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower PSA threshold in Finland (PSA cut-off <4.0 ng/ml)
Number of subjects: 31967
Study 28803925 — intervention group
Group type: COMPARATOR
Intervention: Finnish screening protocol (4-year interval, PSA cut-off 4.0 ng/ml)
Number of subjects: 31967
Study 29048238 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12-containing ointment (M-treatment)
Number of subjects: 24
Study 29048238 — intervention group
Group type: COMPARATOR
Intervention: Glycerol-petrolatum-based emollient cream (C-treatment)
Number of subjects: 24
Study 24284689 — intervention group
Group type: EXPERIMENTAL
Intervention: fixed split‐angle keyboard
Number of subjects: 77
Study 24284689 — intervention group
Group type: COMPARATOR
Intervention: standard flat keyboard
Number of subjects: 77
Study 24226805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted catheter-directed thrombolysis (USAT) with 10 to 20 mg recombinant tissue plasminogen activator over 15 hours
Number of subjects: 59
Study 24226805 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin alone (heparin group)
Number of subjects: 59
Study 24226805 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety outcomes for both groups
Number of subjects: 59
Study 21493314 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold saline-soaked gauze compression
Number of subjects: 300
Study 21493314 — intervention group
Group type: COMPARATOR
Intervention: Dry gauze compression
Number of subjects: 300
Study 17918146 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneVac-B
Number of subjects: 20
Study 17918146 — intervention group
Group type: COMPARATOR
Intervention: Engerix-B
Number of subjects: 20
Study 15553819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen and TFM (tongfei mixture)
Number of subjects: 60
Study 15553819 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 60
Study 15553819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 11489102 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic patient feedback intervention
Number of subjects: 210
Study 11489102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no patient feedback)
Number of subjects: 210
Study 11489102 — intervention group
Group type: EXPERIMENTAL
Intervention: Second intervention group (model of patient feedback)
Number of subjects: 210
Study 9732218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole
Number of subjects: 96
Study 9732218 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 96
Study 8291919 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan) regimen A (100 mg/m2 weekly)
Number of subjects: 25
Study 8291919 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan) regimen C (200 mg/m2 every 3-4 weeks)
Number of subjects: 25
Study 8291919 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan) overall
Number of subjects: 25
Study 8291919 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 (irinotecan)
Number of subjects: 25
Study 8291919 — intervention group
Group type: COMPARATOR
Intervention: CPT-11 (irinotecan) regimen C vs regimen A
Number of subjects: 25
Study 28591084 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ketamine 1 mg/kg instilled in the wound
Number of subjects: 90